Precision BioSciences Sets Priorities for 2026, Unveils Gene Editing Plans.

Precision BioSciences sets strategic priorities for 2026, focusing on the advancement of clinical-stage programs PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy. The Phase 1/2a ELIMINATE-B trial for PBGENE-HBV is ongoing across multiple dosing cohorts, with data updates expected at medical conferences in 2026. PBGENE-DMD is expecting IND clearance in Q1 2026 for the Phase 1/2 FUNCTION-DMD study, with initial data from multiple patients expected in 2026. The company has approximately $137 million in cash, cash equivalents, and restricted cash as of December 31, 2025, anticipated to fund PBGENE-HBV and PBGENE-DMD data milestones through 2028.